×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
🎬
Demo Video
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Demo Video
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Clinical: Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
clinical
4,079 words
KG: Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
Contents
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (49)
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.62
Vagal Afferent Microbial Signal Modulation
Score: 0.62
TREM2-Dependent Microglial Senescence Transition
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
Lysosomal Membrane Repair Enhancement
Score: 0.54
Vocal Cord Neuroplasticity Stimulation
Score: 0.52
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51
← Prev
pg 3/3
Related Analyses (22)
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Show 17 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs
clinical · proposed · Score: 0.90
Brain Connectivity-Targeted tACS Trial in Early AD
clinical · proposed · Score: 0.51
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
clinical · proposed · Score: 0.40
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Anti-Tau Immunotherapy Dosing Optimization
clinical · proposed · Score: 0.40
ApoE4 Function in Alzheimer's Disease
validation · proposed · Score: 0.40
Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
Blood-Based Biomarker Panel for Early AD Detection
clinical · proposed · Score: 0.40
Viral Infections and Alzheimer's Disease — causal mechanisms
clinical · proposed · Score: 0.40
s:** - Test whether HCN1 knockout specifically in EC layer I
falsification · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
SCFA-Mediated Neuroinflammation in Alzheimer's Disease
clinical · proposed · Score: 0.40
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
Sleep Disruption and Alzheimer's Disease — mechanism and int
clinical · proposed · Score: 0.40
Traumatic Brain Injury and Alzheimer's Disease Relationship
validation · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Tau ASO Therapy
validation · proposed · Score: 0.40
Vascular Contribution to Alzheimer's Disease — Beyond Amyloi
validation · proposed · Score: 0.40
Vascular Contributions to Alzheimer Disease and Mixed Pathol
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
Eye-Tracking Digital Markers in Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Gait Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
ASL Perfusion Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
EEG Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Alzheimer's Disease Biomarkers
biomarker · Pages share 18 hypotheses
Blood p-Tau217 as a Clock for Alzheimer's Disease Onset
mechanism · Pages share 18 hypotheses
Blood p-Tau181 and p-Tau217 Elevated in Systemic Amyloi
biomarker · Pages share 18 hypotheses
AT(N) Biomarker Classification for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Combination Biomarker Panels for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
A/T/N+ Comprehensive Biomarker Panel for Alzheimer's Di
biomarker · Pages share 18 hypotheses
Digital Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Astrocyte-Derived Exosomal mRNA Reference Genes for Alz
biomarker · Pages share 18 hypotheses
Dried Blood Spot Biomarker Test for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
DTI Biomarkers for Alzheimer's Disease
biomarker · Pages share 18 hypotheses
GFAP in Alzheimer's Disease
biomarker · Pages share 18 hypotheses
Show 10 more
Knowledge Graph (6 edges)
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
references
APOE
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
references
GFAP
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
references
BDNF
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
references
NLRP3
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
references
C3
Novartis Alzheimer's Disease Phase 2 Trial (NCT07094516)
references
TREM2
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.